Accro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases

Accro Bioscience Inc., a clinical-stage biotechnology company focused on developing innovative therapeutics for immune-mediated diseases, has successfully closed a $50 million Series C financing round. The funding was led by OrbiMed, with significant participation from TCG Crossover, LAV, Cenova Capital, and existing investors Shenzhen Capital Group and Oriza Holdings. This financing, announced on May 18, 2026, will primarily support the advancement of Accro's clinical pipeline, including the Phase IIb trial of its lead candidate, AC-101, for the treatment of Ulcerative Colitis.

Accro Bioscience is at the forefront of developing novel therapeutics that target the molecular mechanisms of regulatory cell death, particularly in the context of inflammatory and autoimmune diseases. The company’s flagship asset, AC-101, is a selective RIPK2 inhibitor that has shown promise in early clinical trials. The funding from this latest round will enable Accro to further its research and development efforts, particularly in the context of Ulcerative Colitis, a chronic inflammatory bowel disease that affects millions of patients worldwide.

The strategic rationale behind this financing is underscored by the growing demand for effective treatments for Ulcerative Colitis and other immune-mediated conditions. The dysregulation of the NOD/RIPK2 signaling pathway has been implicated in various inflammatory diseases, making AC-101 a potentially transformative therapy. The company has already completed Phase I studies demonstrating a favorable safety and pharmacokinetic profile, and has received FDA clearance for its Phase II clinical trial, marking a significant milestone in its development journey.

The participation of prominent investors such as OrbiMed, which manages over $19 billion in healthcare assets, highlights the confidence in Accro's innovative pipeline and the company's potential to deliver groundbreaking therapies. OrbiMed’s investment strategy focuses on supporting healthcare companies that exhibit strong scientific foundations and robust execution capabilities, aligning well with Accro's mission to provide novel oral treatments for patients suffering from immune-mediated diseases.

This financing round comes at a time when the biotechnology sector is experiencing heightened interest and investment, particularly in companies that are developing therapies for chronic and complex diseases. As the market continues to evolve, the successful advancement of Accro Bioscience's clinical programs could not only enhance its competitive positioning but also contribute to the broader landscape of treatments available for patients with Ulcerative Colitis and related conditions. The implications of this funding extend beyond Accro, potentially influencing investor sentiment and funding opportunities within the biotechnology sector as a whole.